CA2640089C — Process for preparing an a2a-adenosine receptor agonist and its polymorphs
Assigned to Gilead Sciences Inc · Expires 2013-07-23 · 13y expired
What this patent protects
Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of the compound: (see above formula) and to methods of isolating a specific polymorph.
USPTO Abstract
Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of the compound: (see above formula) and to methods of isolating a specific polymorph.
Drugs covered by this patent
- regadenoson (Regadenoson) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.